RBM Mechanisms

Constituencies

Board

Executive Committee

Sub-Committee

Working Groups

Subregional networks

Forum

Secretariat

Executive Director

Procurement and Supply Chain Management Working Group workstreams:

  1. ACT/ Artemisinin Mapping [Co-Chair: Malcolm Cutler, Jacques Pilloy]
  2. mHealth-m [Co-Chairs: Don de Savigny, Paul Lalvani]
  3. Forecasting and quantification [Co-Chairs: Sophie Logez, Seydou Doumbia, Edwin de Voogd]
  4. PSM Bottlenecks [Co-Chairs: Lisa Hare, Marlon Banda,]
  5. LLINs [Co-Chairs: TBD]
  6. IRS [Co-Chairs: Rabindra Abeyasinghe, Sivakumaran Murugasmpillay]
  7. RDT/diagnostics scale up [Chair: Jan Jacobs]

This content is available in English only

Procurement and Supply Chain Management Working Group (PSMWG)

Pharmacovigilance Workstream
  • Overview
  • Meetings
  • Reference documents
Leaders:
Prof Alex Dodoo, WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance, University of Ghana Medical School, Ghana
Prof Paul Lalvani, Empower School of Health, India
Dr Shanthi Pal, WHO
RBM Secretariat Focal point:
Dr Jan Van Erps
Tel.: +41 22 791 5867
Next meeting:
TBD


Overview:
PharamacovigilanceThe last few years have seen an increased and concerted effort by several global players including the World Health Organisation, the Roll Back Malaria Partnership and the Bill & Melinda Gates Foundation to provide the tools, interventions and resources needed to control malaria with a view to elimination and eradication as soon as feasible. One of the cornerstones of these campaigns is increased availability of good quality affordable artemisinin-based combination treatment (ACT) for the management of uncomplicated malaria. The aim is to ensure that ACTs are available to everyone who needs them in all settings. Such widespread deployment of ACTs needs to be accompanied by robust pharmacovigilance (PV) systems to assure patient safety.

The efforts of WHO's Collaboration Centre for International Drug Monitoring, the Uppsala Monitoring Centre (UMC) need to be complemented by those of other partners in order to raise the needed funds and provide the expected advocacy and technical assistance to ensure optimum development and deployment of PV systems in countries where ACTs are being rolled out on a large scale.

For further information, please refer to the Pharmacovigilance Work Stream Terms of Reference.

 

Content 2
Content 3